These findings suggest that anti-HBc positivity may be associated with a more severe disease course and reduced treatment efficacy in ITP, highlighting the importance of assessing hepatitis B serological markers when managing ITP patients. This evidence concerns the gene KRT88P and autoimmune thrombocytopenic purpura.